Your browser doesn't support javascript.
loading
Neutralizing Antibody Response to Pseudotype SARS-CoV-2 Differs between mRNA-1273 and BNT162b2 COVID-19 Vaccines and by History of SARS-CoV-2 Infection
Harmony L. Tyner; Mark G. Thompson; Jefferey L. Burgess; Lauren Grant; Manjusha Gaglani; Jennifer L. Kuntz; Allison L. Naleway; Natalie J. Thornburg; Alberto J. Caban-Martinez; Sarang K. Yoon; Meghan K. Herring; Shawn C. Beitel; Lenee Blanton; Janko Nikolich-Zugich; Matthew S. Thiese; Jessica Flores Pleasants; Ashley L. Fowlkes; Karen Lutrick; Kayan Dunnigan; Young M. Yoo; Spencer Rose; Holly Groom; Jennifer Meece; Meredith G. Wesley; Natasha Schaefer-Solle; Paola Louzado-Feliciano; Laura J. Edwards; Lauren E. W. Olsho.
Afiliação
  • Harmony L. Tyner; St. Lukes Regional Health Care System
  • Mark G. Thompson; Centers for Disease Control and Prevention
  • Jefferey L. Burgess; Mel and Enid Zuckerman College of Public Health and the College of Medicine
  • Lauren Grant; Centers for Disease Control and Prevention
  • Manjusha Gaglani; Baylor Scott and White Health and Texas A&M University College of Medicine
  • Jennifer L. Kuntz; Kaiser Permanente Northwest Center for Health Research
  • Allison L. Naleway; Kaiser Permanente Northwest Center for Health Research
  • Natalie J. Thornburg; Centers for Disease Control and Prevention
  • Alberto J. Caban-Martinez; Leonard M. Miller School of Medicine, University of Miami
  • Sarang K. Yoon; Department of Family and Preventive Medicine, University of Utah Health
  • Meghan K. Herring; Abt Associates, Inc.
  • Shawn C. Beitel; Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona
  • Lenee Blanton; Centers for Disease Control and Prevention
  • Janko Nikolich-Zugich; Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona
  • Matthew S. Thiese; Department of Family and Preventive Medicine, University of Utah Health
  • Jessica Flores Pleasants; Abt Associates, Inc.
  • Ashley L. Fowlkes; Centers for Disease Control and Prevention
  • Karen Lutrick; Mel and Enid Zuckerman College of Public Health and the College of Medicine, University of Arizona
  • Kayan Dunnigan; Baylor Scott and White Health
  • Young M. Yoo; Centers for Disease Control and Prevention
  • Spencer Rose; Baylor Scott and White Health
  • Holly Groom; Kaiser Permanente Northwest Center for Health Research
  • Jennifer Meece; Marshfield Clinic Research Institute
  • Meredith G. Wesley; Abt Associates, Inc.
  • Natasha Schaefer-Solle; Leonard M. Miller School of Medicine, University of Miami
  • Paola Louzado-Feliciano; Leonard M. Miller School of Medicine, University of Miami
  • Laura J. Edwards; Abt Associates, Inc.
  • Lauren E. W. Olsho; Abt Associates, Inc.
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21265171
Artigo de periódico
Um artigo publicado em periódico científico está disponível e provavelmente é baseado neste preprint, por meio do reconhecimento de similaridade realizado por uma máquina. A confirmação humana ainda está pendente.
Ver artigo de periódico
ABSTRACT
BackgroundData on the development of neutralizing antibodies against SARS-CoV-2 after SARS-CoV-2 infection and after vaccination with messenger RNA (mRNA) COVID-19 vaccines are limited. MethodsFrom a prospective cohort of 3,975 adult essential and frontline workers tested weekly from August, 2020 to March, 2021 for SARS-CoV-2 infection by Reverse Transcription- Polymerase Chain Reaction (RT-PCR) assay irrespective of symptoms, 497 participants had sera drawn after infection (170), vaccination (327), and after both infection and vaccination (50 from the infection population). Serum was collected after infection and each vaccine dose. Serum- neutralizing antibody titers against USA-WA1/2020-spike pseudotype virus were determined by the 50% inhibitory dilution. Geometric mean titers (GMTs) and corresponding fold increases were calculated using t-tests and linear mixed effects models. ResultsAmong 170 unvaccinated participants with SARS-CoV-2 infection, 158 (93%) developed neutralizing antibodies (nAb) with a GMT of 1,003 (95% CI=766-1,315). Among 139 previously uninfected participants, 138 (99%) developed nAb after mRNA vaccine dose-2 with a GMT of 3,257 (95% CI = 2,596-4,052). GMT was higher among those receiving mRNA-1273 vaccine (GMT =4,698, 95%CI= 3,186-6,926) compared to BNT162b2 vaccine (GMT=2,309, 95%CI=1,825-2,919). Among 32 participants with prior SARS-CoV-2 infection, GMT was 21,655 (95%CI=14,766-31,756) after mRNA vaccine dose-1, without further increase after dose- 2. ConclusionsA single dose of mRNA vaccine after SARS-CoV-2 infection resulted in the highest observed nAb response. Two doses of mRNA vaccine in previously uninfected participants resulted in higher nAb to SARS-CoV-2 than after one dose of vaccine or SARS- CoV-2 infection alone. Neutralizing antibody response also differed by mRNA vaccine product. Main Point SummaryOne dose of mRNA COVID-19 vaccine after previous SARS-CoV-2 infection produced the highest neutralizing antibody titers; among those without history of infection, two doses of mRNA vaccine produced the most robust response.
Licença
cc0
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Estudo observacional / Estudo prognóstico Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint